JY
LENZ

Jeff Yass’s LENZ Therapeutics LENZ Stock Holding History

Jeff Yass’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-110,304
Closed -$889K – 14702
2026
Q1 		$1.01M Buy
110,304
+42,582
+63% +$598K ﹤0.01% 7852
2025
Q4 		$1.08M Buy
67,722
+17,171
+34% +$500K ﹤0.01% 6996
2025
Q3 		$2.35M Buy
50,551
+28,366
+128% +$1.04M ﹤0.01% 5442
2025
Q2 		$650K Buy
22,185
+5,869
+36% +$160K ﹤0.01% 8553
2025
Q1 		$419K Buy
16,316
+8,300
+104% +$204K ﹤0.01% 9300
2024
Q4 		$231K Buy
+8,016
New +$244K ﹤0.01% 10393
2024
Q1 		– Sell
-10,449
Closed -$192K – 13547
2023
Q4 		$192K Buy
10,449
+8,474
+429% +$140K ﹤0.01% 10729
2023
Q3 		$34.3K Buy
+1,975
New +$34.3K ﹤0.01% 11435
2023
Q2 		– Sell
-9,064
Closed -$181K – 13318
2023
Q1 		$155K Buy
9,064
+4,259
+89% +$68.9K ﹤0.01% 10878
2022
Q4 		$112K Buy
+4,805
New +$111K ﹤0.01% 10857

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Jeff Yass's LENZ Position: Q2 2026 in Review

Jeff Yass sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 110,304 shares — an estimated $889K sold.

Jeff Yass first reported a position in LENZ in Q4 2022 and held it in 10 quarters. The position peaked at $2.35M in Q3 2025. 143 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Jeff Yass reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 110,304 LENZ Therapeutics shares in Q2 2026, an estimated $889K.
  • Jeff Yass first reported a position in LENZ Therapeutics in Q4 2022 and held it in 10 quarters.
  • Jeff Yass's LENZ Therapeutics position peaked at $2.35M in Q3 2025.
  • 143 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.